QGEN - QIAGEN N.V.

NYSE - NYSE Delayed Price. Currency in USD
36.64
+0.08 (+0.22%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close36.56
Open36.49
Bid36.81 x 900
Ask36.88 x 1000
Day's Range36.38 - 36.79
52 Week Range31.01 - 39.45
Volume968,143
Avg. Volume1,175,332
Market Cap8.29B
Beta (3Y Monthly)1.18
PE Ratio (TTM)96.17
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
    Zacks3 days ago

    QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

    QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journals9 days ago

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • What Does QIAGEN N.V.’s (NYSE:QGEN) P/E Ratio Tell You?
    Simply Wall St.9 days ago

    What Does QIAGEN N.V.’s (NYSE:QGEN) P/E Ratio Tell You?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how QIAGEN N.V.'s (NYSE:QGEN) P/E Read More...

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Qiagen NV.

    # Qiagen NV ### NYSE:QGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding QGEN is favorable, with net inflows of $15.01 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
    Zacks10 days ago

    QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

    QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

  • Do Hedge Funds Love Qiagen NV (QGEN)?
    Insider Monkeylast month

    Do Hedge Funds Love Qiagen NV (QGEN)?

    Does Qiagen NV (NYSE:QGEN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]

  • Simply Wall St.last month

    Where QIAGEN NV’s (NYSE:QGEN) Earnings Growth Stands Against Its Industry

    When QIAGEN NV (NYSE:QGEN) announced its most recent earnings (30 September 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers Read More...

  • QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
    Zacks2 months ago

    QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach

    The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.

  • QIAGEN's New Offerings to Broaden Hematology Testing Suite
    Zacks2 months ago

    QIAGEN's New Offerings to Broaden Hematology Testing Suite

    QIAGEN (QGEN) continues to progress with test menu expansion.

  • Qiagen (QGEN) Down 3.5% Since Last Earnings Report: Can It Rebound?
    Zacks2 months ago

    Qiagen (QGEN) Down 3.5% Since Last Earnings Report: Can It Rebound?

    Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • With A 3.6% Return On Equity, Is QIAGEN NV (NYSE:QGEN) A Quality Stock?
    Simply Wall St.2 months ago

    With A 3.6% Return On Equity, Is QIAGEN NV (NYSE:QGEN) A Quality Stock?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • Vanguard Health Care Fund Buys 4 Stocks in 3rd Quarter
    GuruFocus.com2 months ago

    Vanguard Health Care Fund Buys 4 Stocks in 3rd Quarter

    The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio last week, listing four new positions. Warning! GuruFocus has detected 1 Warning Sign with ELAN. Managed by Jean Hynes, the fund invests in a number of diverse health care-related stocks from around the world in order to achieve long-term capital appreciation.

  • Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
    Zacks2 months ago

    Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y

    Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.

  • QIAGEN Acquires Growth
    Motley Fool3 months ago

    QIAGEN Acquires Growth

    With lackluster growth, the diagnostic test and lab supplier acquired an option to get into a new diagnostic test market.

  • See what the IHS Markit Score report has to say about Qiagen NV.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Qiagen NV.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of QGEN earnings conference call or presentation 30-Oct-18 1:00pm GMT

    Q3 2018 Qiagen NV Earnings Call

  • Qiagen NV (QGEN) Q3 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Qiagen NV (QGEN) Q3 2018 Earnings Conference Call Transcript

    QGEN earnings call for the period ending September 30, 2018.

  • QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3
    Zacks3 months ago

    QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3

    QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.

  • Qiagen (QGEN) Q3 Earnings Surpass Estimates
    Zacks3 months ago

    Qiagen (QGEN) Q3 Earnings Surpass Estimates

    Qiagen (QGEN) delivered earnings and revenue surprises of 6.06% and -1.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Qiagen: 3Q Earnings Snapshot

    On a per-share basis, the Venlo, Netherlands-based company said it had profit of 26 cents. Earnings, adjusted for amortization costs and restructuring costs, were 35 cents per share. The results beat Wall ...

  • Qiagen (QGEN) Q3 Earnings Preview: What to Look Out For
    Zacks3 months ago

    Qiagen (QGEN) Q3 Earnings Preview: What to Look Out For

    Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite
    Zacks3 months ago

    QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

    QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.

  • QIAGEN Introduces New RNA-seq Library Preparation Solutions
    Zacks3 months ago

    QIAGEN Introduces New RNA-seq Library Preparation Solutions

    QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.

  • Today's Bell Ringer, November 29, 2018
    CNBC Videos2 months ago

    Today's Bell Ringer, November 29, 2018

    Today's bell ringers are Qiagen with CEO Peer Schatz at the NYSE and Gritstone Oncology with co-founder Andrew Allen, at the Nasdaq.